Intellia Therapeutics, Inc. Earnings Per Share Disclosure
13. Loss Per Share
The Company calculates basic loss per share by dividing net loss for each respective period by the weighted average number of common shares outstanding for each respective period. The Company computes diluted loss per share after giving consideration to the dilutive effect of stock options and unvested restricted stock units that are outstanding during the period, except where such securities would be anti-dilutive.
Basic and diluted loss per share was calculated as follows:
|
|
Year Ended December 31, |
|
|||||||||
|
|
2025 |
|
|
2024 |
|
|
2023 |
|
|||
|
|
(In thousands except per share data) |
|
|||||||||
Net loss |
|
$ |
(412,694 |
) |
|
$ |
(519,021 |
) |
|
$ |
(481,192 |
) |
Weighted average shares outstanding, basic |
|
|
108,376 |
|
|
|
98,849 |
|
|
|
88,770 |
|
Net loss per share, basic and diluted |
|
$ |
(3.81 |
) |
|
$ |
(5.25 |
) |
|
$ |
(5.42 |
) |
The following common stock equivalents were excluded from the calculation of diluted loss per share because their inclusion would have been anti-dilutive:
|
|
Year Ended December 31, |
||||
|
|
2025 |
|
2024 |
|
2023 |
|
|
(In thousands) |
||||
Unvested restricted stock units |
|
5,196 |
|
5,547 |
|
4,042 |
Stock options |
|
5,174 |
|
5,413 |
|
5,459 |
|
|
10,370 |
|
10,960 |
|
9,501 |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.